# EBIN (NCT03235245)

> Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03235245
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Unresectable Stage III Melanoma; Stage IV Melanoma
- Interventions: Nivolumab + Ipilimumab; Encorafenib + Binimetinib
- Enrollment: 271
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 7
- Podcasts: 4
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ebin-nct03235245

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03235245", "email": "<work email>"}; the inbox owner confirms by the emailed link.